Study on the mechanism of lupenone for treating type 2 diabetes by integrating pharmacological evaluation and network pharmacology

Autor:	Feng, Xu, Mei, Zhang, Hongmei, Wu, Yuanmin, Wang, Ye, Yang, Xiangpei, Wang
Rok vydání:	2022
Předmět:	Male Pharmacology Pharmaceutical Science General Medicine Network Pharmacology Triterpenes Diabetes Mellitus Experimental Rats Rats Sprague-Dawley Diabetes Mellitus Type 2 Complementary and alternative medicine Drug Discovery Animals Insulin Molecular Medicine Insulin Resistance
Zdroj:	Pharmaceutical Biology. 60:997-1010
ISSN:	1744-5116 1388-0209
Popis:	Lupenone (LUP) is the active ingredient ofAnimal experiments combined with network pharmacology were used to explore the mechanism of LUP for treating diabetes.Insulin resistance (IR) in male Sprague-Dawley rats with type 2 diabetic was induced using a high-fat diet and streptozotocin. The selected rats were divided into normal group, model group, positive group and LUP (2.0, 4.0 and 8.0 mg/kg) groups, and orally administrated twice daily with Tween 80, rosiglitazone or LUP. Fasting blood glucose (FBG), oxidative stress index, blood lipids and IR-related targets were detected. A network pharmacology analysis was performed.Compared to the model group, LUP (8.0 mg/kg) significantly decreased the levels of FBG (22.3%), LEP (9.5%), HbA1c (14.9%) and MDA (12.3%), increased the ADPN (24.2%) levels and GSH-PX activity (12.4%) (The mechanism of LUP for treating diabetes is related to improving IR. LUP has the potential to be developed as a new drug for treating type 2 diabetes.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abd01250aab217450beea14893c9261b https://doi.org/10.1080/13880209.2022.2067568 Zobrazit plný text záznamu Plný text ve formátu PDF